Published in J Cell Biochem Suppl on January 01, 2000
Immobility, inheritance and plasticity of shape of the yeast nucleus. BMC Cell Biol (2007) 0.95
Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population. PLoS One (2011) 0.78
The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens. Biomed Res Int (2017) 0.75
Urine based markers of urological malignancy. J Urol (2001) 1.61
Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol (2000) 1.15
Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res (1994) 1.13
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res (2000) 1.10
Nuclear structural proteins as biomarkers of cancer. J Cell Biochem (1999) 1.08
Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res (1993) 1.05
Cell structure and DNA organization. Crit Rev Eukaryot Gene Expr (1991) 1.00
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol (2001) 0.98
The DNA-binding and tau2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal. Mol Endocrinol (1998) 0.98
Spinal cord compression in prostate cancer. J Neurooncol (1995) 0.97
Association of transcription factors with the nuclear matrix. J Cell Biochem (1996) 0.89
Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate (1998) 0.89
NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells. J Cell Biol (1994) 0.87
Preneoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype. J Natl Cancer Inst (1991) 0.87
Association of vitamin D receptors with the nuclear matrix of human and rat genitourinary tissues. J Steroid Biochem Mol Biol (1998) 0.84
Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol (1998) 0.81
Effect of organ site on nuclear matrix protein composition. J Cell Biochem (1996) 0.81
Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol (1999) 0.81
Use of urine-based markers for detection and monitoring of bladder cancer. Tech Urol (1999) 0.80
Expression patterns of vitamin D receptor in human prostate. J Cell Biochem (2001) 0.80
In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate. J Urol (2000) 0.79
The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ (1996) 0.79
Evaluation of the effect of spinal cord injury on serum PSA levels. Urology (2000) 0.78
Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology (1999) 0.77
The effect of extracellular matrix interactions on morphologic transformation in vitro. Biochem Biophys Res Commun (1991) 0.77
Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests? Postgrad Med (1999) 0.76
Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate. Prostate (1999) 0.76
Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts. Mech Ageing Dev (1992) 0.76
Rat seminal-vesicle secretory protein SVS II binds DNA with a preference for the 5' regulatory region of secretory protein SVS IV gene: co-isolation with components of the nuclear matrix. J Androl (1999) 0.75
Novel therapies for advanced prostate cancer. Semin Urol Oncol (1997) 0.75
The utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr (1996) 0.75